Sarda Proteins Limited (ISIN: INE995U01011) has reported a mixed financial performance for the second quarter and half-year ended September 30, 2025. The company witnessed a significant revenue surge in Q2 but faced challenges over the six-month period.

Q2 Performance Highlights

Sarda Proteins demonstrated strong growth in the second quarter:

• Revenue: Rs 430.38 lakhs
• Net Profit: Rs 40.46 lakhs

This performance indicates a substantial improvement compared to the previous quarter.

Half-Year Results

Despite the positive Q2 results, the half-year figures paint a different picture:

• Revenue: Rs 1,525.84 lakhs
• Net Loss: Rs 8.88 lakhs

The loss over the six-month period suggests volatility in the company's performance.

Balance Sheet Growth

Sarda Proteins reported a remarkable expansion in its balance sheet:

This substantial increase was primarily driven by:

• Higher trade receivables
• Increased advances

Such significant growth in assets indicates a major expansion in the company's business operations during this period.

Historical Performance

To provide context, let's look at the company's annual performance for the fiscal year ended March 31, 2025:

The historical data shows that Sarda Proteins has been experiencing significant year-over-year growth in revenue, although profitability metrics have been volatile.

Conclusion

While the company has shown impressive revenue growth both in the recent quarter and over the past year, the half-year loss and fluctuating profitability metrics suggest that Sarda Proteins may be in a phase of rapid expansion that has yet to translate into consistent bottom-line growth.

The substantial increase in total assets, particularly in receivables and advances, may indicate new business opportunities or expansion. However, it also raises questions about the company's working capital management and the quality of these rapidly growing assets.

As Sarda Proteins navigates this period of significant growth, stakeholders will be keen to see how the company manages its expansion and translates it into sustainable profitability.

Sarda Proteins Limited (SPL) has announced a crucial Board of Directors meeting scheduled for July 26, 2025, set to address several significant matters that could reshape the company's future. The meeting, to be held via video conferencing at 11:00 A.M., will deliberate on a series of important proposals that could potentially transform the company's identity and governance structure.

Proposed Name Change

One of the most notable items on the agenda is the proposal to change the company's name from Sarda Proteins Limited to Onix Power Limited. This potential rebranding suggests a possible shift in the company's focus or expansion into new business areas, although specific reasons for the name change have not been disclosed.

Executive Appointment

The board will consider the appointment of Ms. Rinkal Malviya as a Woman Director in an executive capacity. This move aligns with corporate governance norms that emphasize gender diversity in company leadership and could bring fresh perspectives to the company's executive team.

Registered Office Relocation

Another significant proposal on the table is the shifting of the company's registered office. While the new location has not been specified, such a move could have implications for the company's operations and administrative functions.

Governance and Shareholder Engagement

The meeting will also address key governance matters, including:

1. Approval of the notice for an Extra-Ordinary General Meeting (EGM) to be conducted through video conferencing.
2. Appointment of a scrutinizer for overseeing the voting process.
3. Selection of an e-voting agency to facilitate remote voting for shareholders.

These steps indicate the company's commitment to shareholder engagement and compliance with modern corporate governance practices.

Implications and Next Steps

The outcomes of this board meeting could have far-reaching effects on Sarda Proteins Limited's corporate identity, governance, and potentially its business direction. Shareholders and market observers will be keenly watching for the results of these deliberations and any subsequent announcements.

The company has duly informed the BSE Limited of this upcoming meeting, in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The official communication was signed by Mr. Khilan H. Savaliya, Director of Sarda Proteins Limited.

As these proposals require shareholder approval, the company is expected to provide further details and rationale for these changes in the upcoming EGM notice. Stakeholders are advised to stay tuned for more information as it becomes available following the board meeting on July 26, 2025.